<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Hematol</journal-id><journal-id journal-id-type="iso-abbrev">Ann. Hematol</journal-id><journal-title-group><journal-title>Annals of Hematology</journal-title></journal-title-group><issn pub-type="ppub">0939-5555</issn><issn pub-type="epub">1432-0584</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27696203</article-id><article-id pub-id-type="pmc">5093206</article-id><article-id pub-id-type="publisher-id">2810</article-id><article-id pub-id-type="doi">10.1007/s00277-016-2810-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>All-<italic>trans</italic> retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Schlenk</surname><given-names>Richard F.</given-names></name><address><phone>+49-731-500-45900</phone><email>richard.schlenk@uniklinik-ulm.de</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>L&#x000fc;bbert</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Benner</surname><given-names>Axel</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Lamparter</surname><given-names>Alexander</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Krauter</surname><given-names>J&#x000fc;rgen</given-names></name><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Herr</surname><given-names>Wolfgang</given-names></name><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Martin</surname><given-names>Hans</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Salih</surname><given-names>Helmut R.</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>K&#x000fc;ndgen</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Horst</surname><given-names>Heinz-A.</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Brossart</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>G&#x000f6;tze</surname><given-names>Katharina</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Nachbaur</surname><given-names>David</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>Wattad</surname><given-names>Mohammed</given-names></name><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name><surname>K&#x000f6;hne</surname><given-names>Claus-Henning</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Fiedler</surname><given-names>Walter</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name><surname>Bentz</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name><surname>Wulf</surname><given-names>Gerald</given-names></name><xref ref-type="aff" rid="Aff20">20</xref></contrib><contrib contrib-type="author"><name><surname>Held</surname><given-names>Gerhard</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name><surname>Hertenstein</surname><given-names>Bernd</given-names></name><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name><surname>Salwender</surname><given-names>Hans</given-names></name><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author"><name><surname>Gaidzik</surname><given-names>Verena I</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Schlegelberger</surname><given-names>Brigitte</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name><surname>Weber</surname><given-names>Daniela</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>D&#x000f6;hner</surname><given-names>Konstanze</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ganser</surname><given-names>Arnold</given-names></name><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author"><name><surname>D&#x000f6;hner</surname><given-names>Hartmut</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><collab>for the German-Austrian Acute Myeloid Leukemia Study Group</collab></contrib><aff id="Aff1"><label>1</label>Department of Internal Medicine III, University Hospital of Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany </aff><aff id="Aff2"><label>2</label>National Center for Tumor Diseases (NCT), German Cancer Research Center, Heidelberg, Germany </aff><aff id="Aff3"><label>3</label>Department of Hematology and Oncology, University Hospital of Freiburg, Freiburg, Germany </aff><aff id="Aff4"><label>4</label>Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany </aff><aff id="Aff5"><label>5</label>Department of Oncology and Hematology, Klinikum Braunschweig, Braunschweig, Germany </aff><aff id="Aff6"><label>6</label>Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany </aff><aff id="Aff7"><label>7</label>Department of Medicine III, Johannes Gutenberg-University Mainz, Mainz, Germany </aff><aff id="Aff8"><label>8</label>Department of Internal Medicine III, University of Regensburg, Regensburg, Germany </aff><aff id="Aff9"><label>9</label>Department of Internal Medicine II, University Hospital, Frankfurt, Germany </aff><aff id="Aff10"><label>10</label>Department of Hematology and Oncology, Eberhard-Karls University, T&#x000fc;bingen, Germany </aff><aff id="Aff11"><label>11</label>Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University D&#x000fc;sseldorf, D&#x000fc;sseldorf, Germany </aff><aff id="Aff12"><label>12</label>Department of Internal Medicine II, University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany </aff><aff id="Aff13"><label>13</label>Department of Internal Medicine III, University Hospital of Bonn, Bonn, Germany </aff><aff id="Aff14"><label>14</label>Department of Internal Medicine III, Technical University of Munich, Munich, Germany </aff><aff id="Aff15"><label>15</label>Department of Internal Medicine V, University Hospital Innsbruck, Innsbruck, Austria </aff><aff id="Aff16"><label>16</label>Department of Hematology, Oncology and Stem Cell Transplantation, Klinikum Essen S&#x000fc;d, Essen, Germany </aff><aff id="Aff17"><label>17</label>Department of Oncology and Hematology, Klinikum Oldenburg, Oldenburg, Germany </aff><aff id="Aff18"><label>18</label>Department of Internal Medicine II, University Medical Center Hamburg-Eppendorf, Hamburg, Germany </aff><aff id="Aff19"><label>19</label>Department of Internal Medicine III, St&#x000e4;dtisches Klinikum Karlsruhe, Karlsruhe, Germany </aff><aff id="Aff20"><label>20</label>Department of Hematology and Oncology, University Hospital of G&#x000f6;ttingen, G&#x000f6;ttingen, Germany </aff><aff id="Aff21"><label>21</label>Department of Internal Medicine I, University Hospital of Saarland, Homburg, Germany </aff><aff id="Aff22"><label>22</label>Department of Internal Medicine I, Klinikum Bremen Mitte, Bremen, Germany </aff><aff id="Aff23"><label>23</label>Department of Hematology/Oncology, Asklepios Klinik Altona, Hamburg, Germany </aff><aff id="Aff24"><label>24</label>Institute of Human Genetics, Hannover Medical School, Hannover, Germany </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>3</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="ppub"><year>2016</year></pub-date><volume>95</volume><issue>12</issue><fpage>1931</fpage><lpage>1942</lpage><history><date date-type="received"><day>17</day><month>8</month><year>2016</year></date><date date-type="accepted"><day>23</day><month>8</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><p>The aim of this clinical trial was to evaluate the impact of all-<italic>trans</italic> retinoic acid (ATRA) in combination with chemotherapy and to assess the <italic>NPM1</italic> status as biomarker for ATRA therapy in younger adult patients (18&#x02013;60&#x000a0;years) with acute myeloid leukemia (AML). Patients were randomized for intensive chemotherapy with or without open-label ATRA (45&#x000a0;mg/m<sup>2</sup>, days 6&#x02013;8; 15&#x000a0;mg/m<sup>2</sup>, days 9&#x02013;21). Two cycles of induction therapy were followed by risk-adapted consolidation with high-dose cytarabine or allogeneic hematopoietic cell transplantation. Due to the open label character of the study, analysis was performed on an intention-to-treat (ITT) and a per-protocol (PP) basis. One thousand one hundred patients were randomized (556, STANDARD; 544, ATRA) with 38 patients treated vice versa. Median follow-up for survival was 5.2&#x000a0;years. ITT analyses revealed no difference between ATRA and STANDARD for the total cohort and for the subset of <italic>NPM1</italic>-mutated AML with respect to event-free (EFS; <italic>p</italic>&#x02009;=&#x02009;0.93, <italic>p</italic>&#x02009;=&#x02009;0.17) and overall survival (OS; <italic>p</italic>&#x02009;=&#x02009;0.24 and <italic>p</italic>&#x02009;=&#x02009;0.32, respectively). Pre-specified PP analyses revealed better EFS in <italic>NPM1</italic>-mutated AML (<italic>p</italic>&#x02009;=&#x02009;0.05) and better OS in the total cohort (<italic>p</italic>&#x02009;=&#x02009;0.03). Explorative subgroup analyses on an ITT basis revealed better OS (<italic>p</italic>&#x02009;=&#x02009;0.05) in ATRA for genetic low-risk patients according to ELN recommendations. The clinical trial is registered at clinicaltrialsregister.eu (EudraCT Number: 2004-004321-95).</p><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1007/s00277-016-2810-z) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Acute myeloid leukemia</kwd><kwd>All-<italic>trans</italic> retinoic acid</kwd><kwd>Nucleophosmin-1</kwd></kwd-group><funding-group><award-group><funding-source><institution>German Bundesministerium f&#x000fc;r Bildung und Forschung</institution></funding-source><award-id>01KG0605</award-id><principal-award-recipient><name><surname>D&#x000f6;hner</surname><given-names>Hartmut</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution>German Bundesministerium f&#x000fc;r Bildung und Forschung</institution></funding-source><award-id>01GI9981</award-id><principal-award-recipient><name><surname>D&#x000f6;hner</surname><given-names>Hartmut</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>DFG FI405/5-1, BU 1339/3-1 and BU 1339/5-1, SFB 1074 B3</award-id><principal-award-recipient><name><surname>D&#x000f6;hner</surname><given-names>Hartmut</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution>Deutsche Jos&#x000e9; Carreras Leuk&#x000e4;mie-Stiftung</institution></funding-source></award-group><award-group><funding-source><institution>Pfizer germany</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag Berlin Heidelberg 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>All-<italic>trans</italic> retinoic acid (ATRA) in combination with chemotherapy or arsenic trioxide (ATO) has revolutionized the treatment of acute promyelocytic leukemia (APL) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. However, early preclinical studies also provided a rationale for the use of ATRA in non-APL acute myeloid leukemia (AML) [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>]. <italic>In vitro</italic> studies showed efficacy of ATRA in non-APL AML cell lines and primary AML blasts, especially in co-treatment of leukemic blasts with cytarabine [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>] or idarubicin [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p>These <italic>in vitro</italic> experiments provided important evidence that the addition of ATRA to cytarabine or idarubicin only increases the killing of clonogenic cells when ATRA is administered after exposure to the cytotoxic drug [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. Besides a shortening of the BCL2 half-life, which has been implicated as a resistance mechanism in AML [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>], an additional potential pathophysiological mechanism of the anti-leukemic activity of ATRA was described by Balusu et al. in AML with mutant <italic>NPM1</italic> [<xref ref-type="bibr" rid="CR11">11</xref>]. NPM1 levels attenuated by ATRA selectively induced apoptosis and sensitized AML with mutant <italic>NPM1</italic> to treatment with ATRA and cytarabine [<xref ref-type="bibr" rid="CR11">11</xref>]. More recently, two groups showed that the combination of ATRA and ATO synergistically induced proteasomal degradation of mutant NPM1, leading to growth arrest, differentiation and apoptosis [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>].</p><p>Based on the promising <italic>in vitro</italic> data, several clinical trials evaluated ATRA in combination with chemotherapy in non-APL AML. Encouraging data from a phase II trial combining low-dose cytarabine with ATRA in 33 patients ineligible for intensive therapy [<xref ref-type="bibr" rid="CR14">14</xref>] triggered larger up-front randomized trials [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>]. The results from these randomized studies have been contradictory, with the majority reporting negative results. In the study by Estey et al. of 215 patients with high-risk myelodysplastic syndrome or AML older than 71&#x000a0;years, there was no effect of ATRA in multivariable analysis, but a significantly better overall survival was found in univariable analyses for patients treated in the ATRA arms [<xref ref-type="bibr" rid="CR15">15</xref>]. The British Medical Research Council (MRC) performed three randomized trials, one in younger patients receiving intensive first-line treatment (MRC AML12, <italic>n</italic>&#x02009;=&#x02009;1097) [<xref ref-type="bibr" rid="CR16">16</xref>], one in medically unfit patients (MRC AML14, <italic>n</italic>&#x02009;=&#x02009;207) [<xref ref-type="bibr" rid="CR17">17</xref>], and one in high-risk refractory or relapsed patients (MRC AML-HR, <italic>n</italic>&#x02009;=&#x02009;362) [<xref ref-type="bibr" rid="CR18">18</xref>], without showing a significant effect of ATRA on any endpoint analyzed.</p><p>In these trials showing negative results, ATRA consistently was started simultaneously [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>] or before initiation of chemotherapy [<xref ref-type="bibr" rid="CR15">15</xref>]. In contrast, in our AMLHD98B trial of 242 older patients, ATRA was started at the end of chemotherapy in accordance with the <italic>in vitro</italic> data [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. In this trial, patients randomized to the ATRA arm had a significantly higher complete remission (CR) rate, better event-free and overall survival [<xref ref-type="bibr" rid="CR19">19</xref>]. In a subsequent subgroup analysis of the up-front randomized patients (206 of 242), the genotype mutated <italic>NPM1</italic> in the absence of <italic>FLT3</italic> internal tandem duplication (ITD) emerged as a predictive marker for the beneficial effect of ATRA [<xref ref-type="bibr" rid="CR20">20</xref>]. However, similar biomarker analyses on selected patients (592 of 1075) of the MRC AML 12 trial again did not reveal a beneficial clinical effect of ATRA in any of the analyzed subgroups [<xref ref-type="bibr" rid="CR21">21</xref>]. Although not statistically significant but consistent with the results of the AMLHD98B trial, a better relapse-free and overall survival was present in patients exhibiting the genotype mutated <italic>NPM1</italic> in the absence of <italic>FLT3</italic>-ITD who had been randomized to the ATRA arm (estimated hazard ratio for overall survival, 0.70; 95&#x000a0;% confidence interval [CI], 0.42&#x02013;1.16) [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p>In 2004, we initiated the up-front randomized AMLSG 07-04 four-arm study evaluating in a two-by-two factorial design ATRA and valproic acid (VPA) as adjunct to intensive induction and consolidation therapy. In 2006, the protocol was amended and the randomization for VPA was terminated based on excessive hematologic toxicity of VPA in combination with chemotherapy, which was similarly noted in older patients [<xref ref-type="bibr" rid="CR22">22</xref>]. Here, we report the results of the upfront randomization for ATRA in 1100 younger adult patients.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Patients and methods</title><sec id="Sec3"><title>Patients</title><p>Patients aged between 18 and 60&#x000a0;years with newly diagnosed AML including <italic>de novo</italic> AML, secondary AML with a preceding history of myelodysplastic or myeloproliferative disorder (sAML) and therapy-related AML following treatment of a primary malignancy (tAML), as defined by the WHO 2001 classification were eligible for the trial [<xref ref-type="bibr" rid="CR23">23</xref>]. Patients with acute promyelocytic leukemia (APL) as well as patients with concomitant renal (creatinine&#x02009;&#x0003e;&#x02009;1.5&#x000a0;x&#x000a0;upper normal serum level), liver (bilirubin, AST or AP&#x02009;&#x0003e;&#x02009;2&#x000a0;x&#x000a0;upper normal serum level) or cardiac dysfunction (New York Heart Association III/IV), uncontrolled infectious disease, primary coagulation disturbance or performance status (ECOG) &#x0003e;2 were excluded. Written informed consent was obtained from all patients. The protocol was approved by the lead Ethics Review Committee and registered at clinicaltrialsregister.eu (EudraCT Number: 2004-004321-95) and clinicaltrials.gov (NCT00151242).</p></sec><sec id="Sec4"><title>Cyto- and molecular genetics</title><p>Chromosome banding analysis was performed centrally in the two AMLSG Laboratories for Cytogenetics (Hannover, Ulm). Karyotypes were designated according to the International System for Human Cytogenetic Nomenclature [<xref ref-type="bibr" rid="CR24">24</xref>]. Leukemia samples were analyzed for mutations in <italic>FLT3</italic> (ITDs and tyrosine kinase domain [TKD] mutations at codons D835/I836), <italic>NPM1</italic>, <italic>CEBPA</italic>, <italic>DNMT3A, RUNX1</italic>, <italic>IDH1/2</italic>, <italic>ASXL1</italic> and <italic>CEBPA</italic> as previously described [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref>].</p></sec><sec id="Sec5"><title>Study design</title><sec id="Sec6"><title>Induction therapy</title><p>From August 2004 to January 2006, patients were randomized in a two-by-two factorial design to receive induction chemotherapy with or without ATRA and with or without VPA resulting in four arms, ATRA, ATRA-VPA, VPA and STANDARD. In January 2006, randomization for VPA was terminated due to increased hematologic toxicity whereas randomization for ATRA was carried forward. Induction therapy consisted of 2 cycles ICE (idarubicin, 12&#x000a0;mg/m<sup>2</sup> i.v., days 1, 3 and 5; cytarabine, 100&#x000a0;mg/m<sup>2</sup> cont. i.v., days 1&#x02013;7; etoposide 100&#x000a0;mg/m<sup>2</sup> i.v., days 1&#x02013;3) or the same chemotherapy plus ATRA (ATRA p.o., 45&#x000a0;mg/m<sup>2</sup>, days 6&#x02013;8 and 15&#x000a0;mg/m<sup>2</sup>, days 9&#x02013;21). Patients achieving a CR or partial remission (PR) after the first induction received a second cycle according to their initial randomization with a reduced dosage of idarubicin (12&#x000a0;mg/m<sup>2</sup>, days 1 and 3).</p></sec><sec id="Sec7"><title>Consolidation therapy</title><p>Patients with high-risk AML defined either by high-risk cytogenetics or induction failure [<xref ref-type="bibr" rid="CR30">30</xref>] were assigned to receive an allogeneic hematopoietic cell transplantation (HCT) from a matched related (MRD) or unrelated donor (MUD). Starting from December 2006, AML exhibiting a <italic>FLT3</italic>-ITD was also categorized as high risk [<xref ref-type="bibr" rid="CR25">25</xref>]. All other patients were assigned either to three cycles of high-dose cytarabine (HiDAC) from August 2004 to November 2006 with cytarabine 3&#x000a0;g/m<sup>2</sup> bid, days 1, 3 and 5, and from November 2006 with a condensed schedule with application of cytarabine 3&#x000a0;g/m<sup>2</sup> bid, days 1, 2 and 3. If an MRD was available, an allogeneic HCT was intended in first CR in all patients except those with core-binding factor AML.</p></sec></sec><sec id="Sec8"><title>Definition of response criteria, survival endpoints and hematologic recovery</title><p>In accordance with standard criteria, CR was defined as less than 5&#x000a0;% bone marrow blasts, an absolute neutrophil count of 1.0&#x000a0;G/L or higher, a platelet count of 100&#x000a0;G/L or higher, no blasts in the peripheral blood and no extramedullary leukemia; CR with incomplete blood count recovery (CRi) was characterized as CR except for residual neutropenia (neutrophils &#x0003c;1.0&#x000a0;G/L) or thrombocytopenia (platelets &#x0003c;100&#x000a0;G/L) [<xref ref-type="bibr" rid="CR31">31</xref>]. Relapse was defined as more than 5&#x000a0;% bone marrow blasts unrelated to recovery from the preceding course of chemotherapy or new extramedullary leukemia in patients with previously documented CR.</p><p>Event-free survival (EFS), relapse-free survival (RFS) and overall survival (OS) were defined as recommended [<xref ref-type="bibr" rid="CR31">31</xref>]. Times to leukocyte, neutrophil and platelet recovery were measured from the first day of chemotherapy of each cycle until the first day with values more than or equal to 1, 0.5 and 20&#x000a0;G/L for white blood cells (WBC), neutrophils and platelets, respectively. Toxicities were defined and graded according to the National Cancer Institute (NCI) Common Toxicity Criteria, version 2.0.</p></sec><sec id="Sec9"><title>Statistical analysis</title><p>Pairwise comparisons between patient subgroups were performed by the Mann-Whitney or Kruskal-Wallis test for continuous variables and by Fisher&#x02019;s exact test for categorical variables. Univariable and multivariable logistic regression models were applied to investigate the influence of covariates on response to induction therapy.</p><p>The analysis were performed on an intention-to-treat (ITT) according to initial randomization result and a per protocol (PP) basis according to received treatment. The primary endpoint of the study was EFS; secondary endpoints were OS, RFS, therapy-related toxicity and their correlation with the study drug. The median duration of follow-up was calculated by the reverse Kaplan-Meier estimate [<xref ref-type="bibr" rid="CR32">32</xref>]; the Kaplan-Meier method was used to estimate the distributions of EFS, RFS and OS. Survival distributions were compared using the log-rank test. Multivariable Andersen-Gill regression models were used to evaluate prognostic variables including allogeneic HCT as a time-dependent covariable [<xref ref-type="bibr" rid="CR33">33</xref>]. In addition, the following variables were evaluated in multivariable regression models: WBC (median-dichotomized), age, gender, genetic-risk group according to European LeukemiaNet (ELN) recommendations (favorable, intermediate-1, intermediate-2, adverse) [<xref ref-type="bibr" rid="CR34">34</xref>], type of AML (<italic>de novo</italic>, sAML/tAML), randomization (STANDARD, ATRA), <italic>FLT3-</italic>TKD, <italic>FLT3-</italic>ITD, <italic>NPM1</italic>, biallelic mutated <italic>CEBPA</italic>, <italic>DNMT3A</italic>; <italic>IDH1</italic>, <italic>IDH2</italic>, <italic>RUNX1</italic> and <italic>ASXL1</italic> mutational status and VPA (received, not received). Pre-specified subset analyses, according to the <italic>NPM1</italic> and the combined <italic>NPM1</italic> and <italic>FLT3</italic>-ITD mutational status, were performed for all endpoints. Missing data were replaced by 50 imputations using multivariate imputations by chained equations applying predictive mean matching [<xref ref-type="bibr" rid="CR35">35</xref>]. Backward selection applying a stopping rule based on a <italic>p</italic> value of 0.50 was used in multivariable regression models to exclude redundant or unnecessary variables [<xref ref-type="bibr" rid="CR35">35</xref>].</p><p>All statistical analyses were performed with the statistical software environment R, version 3.0.1, using the R packages rms, version 3.6-3, and cmprsk, version 2.2-2 [<xref ref-type="bibr" rid="CR36">36</xref>].</p></sec></sec><sec id="Sec10" sec-type="results"><title>Results</title><sec id="Sec11"><title>Patients and baseline characteristics</title><p>A total of 1229 patients were registered, 809 were randomized first within the framework of the cooperative German AML Intergroup Study [<xref ref-type="bibr" rid="CR37">37</xref>] in a ratio 1:10 into a common standard arm (<italic>n</italic>&#x02009;=&#x02009;85) or the study group specific protocol (<italic>n</italic>&#x02009;=&#x02009;724), and thereafter, 420 patients were directly registered for the AMLSG 07-04 protocol. Of 1144 randomized patients, 44 were excluded due to violation of in-/exclusion criteria (<italic>n</italic>&#x02009;=&#x02009;29), no informed consent (<italic>n</italic>&#x02009;=&#x02009;10) or other reasons (<italic>n</italic>&#x02009;=&#x02009;5).</p><p>Between August 2004 and January 2006, patients were assigned to one of four arms according to the two-by-two factorial design, ATRA (<italic>n</italic>&#x02009;=&#x02009;97), ATRA-VPA (<italic>n</italic>&#x02009;=&#x02009;91), VPA (<italic>n</italic>&#x02009;=&#x02009;95) and STANDARD (<italic>n</italic>&#x02009;=&#x02009;98). After termination of the VPA-randomization, additional <italic>n</italic>&#x02009;=&#x02009;719 patients were randomized for ATRA resulting in 544 patients in the ATRA (ATRA) and 556 in the STANDARD arm of the study (Table <xref rid="Tab1" ref-type="table">1</xref>). Table <xref rid="Tab1" ref-type="table">1</xref> shows patient demographics and presenting laboratory and genetic characteristics by up-front randomization for ATRA. Patients in ATRA were characterized by significantly lower WBC (<italic>p</italic>&#x02009;=&#x02009;0.003) and peripheral blast percentage (<italic>p</italic>&#x02009;=&#x02009;0.003) compared to patients in STANDARD. Nine randomized patients did not receive the scheduled therapy, due to death before start of induction therapy (ATRA, <italic>n</italic>&#x02009;=&#x02009;4; ATRA-VPA, <italic>n</italic>&#x02009;=&#x02009;2; VPA, <italic>n</italic>&#x02009;=&#x02009;0; STANDARD, <italic>n</italic>&#x02009;=&#x02009;3).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Description of patient characteristics, clinical and laboratory</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3"/><th>Standard</th><th>ATRA</th><th rowspan="3">
<italic>p</italic> value</th></tr><tr><th>
<italic>n</italic>&#x02009;=&#x02009;556</th><th>
<italic>n</italic>&#x02009;=&#x02009;544</th></tr><tr><th>No. (%)</th><th>No. (%)</th></tr></thead><tbody><tr><td>Age [years], median (range)</td><td>48.8 (18&#x02013;61)</td><td>48.5 (18&#x02013;61)</td><td>0.56</td></tr><tr><td>Gender [male], No. (%)</td><td>283 (50.9)</td><td>288 (52.9)</td><td>0.51</td></tr><tr><td>WBC [109/l], median (range)</td><td>16.0 (0.3&#x02013;532)</td><td>9.2 (0.3&#x02013;349)</td><td>0.003</td></tr><tr><td>&#x02003;Missing</td><td>3</td><td>8</td><td/></tr><tr><td>Platelets [10<sup>9</sup>/l], median (range)</td><td>52 (3&#x02013;590)</td><td>58 (4&#x02013;933)</td><td>0.11</td></tr><tr><td>&#x02003;Missing</td><td>4</td><td>8</td><td/></tr><tr><td>Hemoglobin [g/dL], (median, range)</td><td>9.1 (3.8&#x02013;15.3)</td><td>9.2 (3.5&#x02013;16.0)</td><td>0.77</td></tr><tr><td>&#x02003;Missings</td><td>3</td><td>7</td><td/></tr><tr><td>LDH [U/l], median (range)</td><td>445 (94&#x02013;15098)</td><td>407.5 (84&#x02013;6907)</td><td>0.18</td></tr><tr><td>&#x02003;Missings</td><td>8</td><td>8</td><td/></tr><tr><td>BM-blasts [%], median (range)*</td><td>75 (0&#x02013;100)</td><td>70 (2&#x02013;100)</td><td>0.14</td></tr><tr><td>&#x02003;Missings</td><td>30</td><td>33</td><td/></tr><tr><td>PB-blasts [%], median (range)</td><td>36 (0&#x02013;100)</td><td>27 (0&#x02013;100)</td><td>0.003</td></tr><tr><td>&#x02003;Missings</td><td>39</td><td>36</td><td/></tr><tr><td>Type of AML, No. (%)</td><td/><td/><td>0.99</td></tr><tr><td>&#x02003;De novo</td><td>484 (87)</td><td>473 (87)</td><td/></tr><tr><td>&#x02003;sAML</td><td>31 (5.6)</td><td>30 (5.5)</td><td/></tr><tr><td>&#x02003;tAML</td><td>40 (7.2)</td><td>40(7.4)</td><td/></tr><tr><td>Cytogenetic risk, No. (%)</td><td/><td/><td>0.58</td></tr><tr><td>&#x02003;CBF-AML</td><td>65 (12.8)</td><td>56 (11.0)</td><td/></tr><tr><td>&#x02003;Intermediate</td><td>336 (66.1)</td><td>338 (66.1)</td><td/></tr><tr><td>&#x02003;Adverse<sup>30</sup>
</td><td>107 (21.1)</td><td>117 (22.9)</td><td/></tr><tr><td>&#x02003;Normal karyotype, No. (%)</td><td>246 (48.4)</td><td>248 (48.5)</td><td>0.99</td></tr><tr><td>&#x02003;Missings</td><td>48</td><td>33</td><td/></tr><tr><td>Biallelic mutated <italic>CEBPA</italic>, No. (%)</td><td>26 (5.3)</td><td>23 (4.8)</td><td>0.77</td></tr><tr><td>&#x02003;Missings</td><td>61</td><td>64</td><td/></tr><tr><td>
<italic>FLT3</italic>-ITD, No. (%)</td><td>107 (20.2)</td><td>102 (20.1)</td><td>0.99</td></tr><tr><td>&#x02003;Missings</td><td>26</td><td>36</td><td/></tr><tr><td>
<italic>FLT3</italic>-TKD, No. (%)</td><td>28 (5.3)</td><td>25 (5.0)</td><td>0.89</td></tr><tr><td>&#x02003;Missings</td><td>29</td><td>40</td><td/></tr><tr><td>Mutated <italic>NPM1</italic>, No. (%)</td><td>149 (29.2)</td><td>138 (27.8)</td><td>0.68</td></tr><tr><td>&#x02003;Missings</td><td>46</td><td>47</td><td/></tr><tr><td>Mutated <italic>DNMT3A</italic>, No. (%)</td><td>109 (21.5)</td><td>119 (23.9)</td><td>0.37</td></tr><tr><td>&#x02003;Missings</td><td>48</td><td>47</td><td/></tr><tr><td>Mutated <italic>IDH1</italic>, No. (%)</td><td>26 (6.1)</td><td>29 (6.8)</td><td>0.68</td></tr><tr><td>&#x02003;Missings</td><td>127</td><td>120</td><td/></tr><tr><td>Mutated <italic>IDH2</italic>R140, No. (%)</td><td>30 (7.0)</td><td>29 (6.9)</td><td>0.99</td></tr><tr><td>Mutated <italic>IDH2</italic>R172, No. (%)</td><td>12 (2.8)</td><td>11 (2.6)</td><td/></tr><tr><td>&#x02003;Missings</td><td>130</td><td>122</td><td/></tr><tr><td>Mutated <italic>RUNX1</italic>, No. (%)</td><td>39 (9.4)</td><td>32 (7.9)</td><td>0.54</td></tr><tr><td>&#x02003;Missings</td><td>139</td><td>140</td><td/></tr><tr><td>Mutated <italic>ASXL1</italic>, No. (%)</td><td>22 (5.3)</td><td>21 (5.1)</td><td>0.99</td></tr><tr><td>&#x02003;Missings</td><td>141</td><td>131</td><td/></tr><tr><td>ELN genetic risk group</td><td/><td/><td>0.80</td></tr><tr><td>&#x02003;Favorable risk, No. (%)</td><td>152 (30.3)</td><td>139 (28.0)</td><td/></tr><tr><td>&#x02003;Intermediate-2 risk, No. (%)</td><td>153 (30.5)</td><td>151 (30.4)</td><td/></tr><tr><td>&#x02003;Intermediate-2 risk, No. (%)</td><td>90 (17.9)</td><td>90 (18.1)</td><td/></tr><tr><td>&#x02003;Adverse risk, No. (%)</td><td>107 (21.3)</td><td>117 (23.5)</td><td/></tr><tr><td>&#x02003;Missings</td><td>54</td><td>47</td><td/></tr></tbody></table><table-wrap-foot><p>
<italic>Abbreviations</italic>: <italic>WBC</italic> white blood count, <italic>LDH</italic> lactate-dehydrogenase, <italic>BM</italic> bone marrow, <italic>PB</italic> peripheral blood, <italic>sAML</italic> secondary AML after a preceding MDS; <italic>tAML</italic> treatment-related AML, <italic>CBF- AML</italic> core-binding factor AML, <italic>CEBPA</italic> CCAAT/enhancer binding protein alpha, <italic>FLT3-ITD</italic> FMS-like tyrosine kinase 3 gene internal tandem duplication, <italic>FLT3-TKD</italic> FMS-like tyrosine kinase 3 gene tyrosine kinase domain mutation, <italic>NPM1</italic> nucleophosmin, <italic>DNMT3A</italic> DNA (cytosine-5-)-methyltransferase 3 alpha, <italic>IDH</italic> Isocitrate dehydrogenase, <italic>RUNX1</italic> Runt-related transcription factor 1, <italic>ASXL1</italic> additional sex combs like 1, transcriptional regulator</p><p>*In case of BM blasts &#x0003c;20&#x000a0;%, diagnosis of AML was established based on extramedullary disease or PB blast &#x0003e;20&#x000a0;%</p></table-wrap-foot></table-wrap>
</p><p>In spite of the initial randomization to ATRA, 19 patients did not receive ATRA due to the local physicians&#x02019; judgment. On the other hand, 19 patients received ATRA although randomized to STANDARD. According to the protocol and the open-label character of the study, ITT analyses followed by PP analyses were performed.</p><p>The trial flow is summarized in the diagram according to CONSORT statement in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>Flow chart on study conduct. Flow chart showing enrollment, program completion and/or drop-out according to the randomization result. Abbreviations: <italic>IC</italic> informed consent, <italic>RD</italic> refractory disease, <italic>HCT</italic> hematopoietic cell transplantation</p></caption><graphic xlink:href="277_2016_2810_Fig1_HTML" id="MO1"/></fig>
</p></sec><sec id="Sec12"><title>Response to induction therapy</title><p>After the first induction cycle, there was no significant difference between the two treatment arms on an ITT basis (ATRA, 50.9&#x000a0;%; STANDARD, 48.7&#x000a0;%) in achieving of CR/CRi (<italic>p</italic>&#x02009;=&#x02009;0.47). In contrast, the PP analysis revealed a significantly (<italic>p</italic>&#x02009;=&#x02009;0.03) higher CR/CRi rate in the ATRA (53.1&#x000a0;%) compared to the STANDARD arm (46.6&#x000a0;%). After double induction therapy, ITT analyses did not reveal a significant difference in CR/CRi rate (<italic>p</italic>&#x02009;=&#x02009;0.95) between ATRA (73.3&#x000a0;%) and STANDARD (73.6&#x000a0;%), whereas in the PP analyses the CR/CRi rate in patients receiving ATRA (75.9&#x000a0;%) was in trend superior (<italic>p</italic>&#x02009;=&#x02009;0.08) compared to patients in STANDARD (71.0&#x000a0;%). In the predefined <italic>NPM1</italic>-subsets (accounted for <italic>FLT3</italic>-ITD), no significant difference were identified.</p><p>Multivariable logistic regression analysis in all patients revealed no impact of ATRA on an ITT and PP basis (Supplementary Table <xref rid="MOESM4" ref-type="media">1</xref>).</p><p>In patients receiving ATRA, a low (2&#x000a0;%) but significantly (<italic>p</italic>&#x02009;=&#x02009;0.04) increased rate of allergic reactions grade III/IV was reported compared to STANDARD (1&#x000a0;%). Of note, in STANDARD cardiac grade III/IV events were significantly (<italic>p</italic>&#x02009;=&#x02009;0.03) more frequent (4&#x000a0;%) compared to ATRA (1.5&#x000a0;%). All other reported toxicities were equally distributed (Supplementary Table <xref rid="MOESM5" ref-type="media">2</xref>). No difference (<italic>p</italic>&#x02009;=&#x02009;0.80) in death rate during double induction therapy was present between ATRA (5.7&#x000a0;%) and STANDARD (6.1&#x000a0;%). Recovery times of neutrophils (<italic>p</italic>&#x02009;=&#x02009;0.61) and platelets (<italic>p</italic>&#x02009;=&#x02009;0.70) after the first induction cycle were comparable between STANDARD and ATRA.</p></sec><sec id="Sec13"><title>Consolidation therapy</title><p>Allogeneic HCT in first CR after first or second induction therapy was performed in 57 and 62 patients in STANDARD and ATRA, respectively; in addition, 50 and 52 patients in STANDARD and ATRA with RD after induction therapy received allogeneic HCT in first CR following successful salvage therapy outside the protocol (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).</p><p>One consolidation therapy with high-dose cytarabine was administered in 272 and 256 patients in STANDARD and ATRA, respectively; all three cycles of high-dose cytarabine were administered in 192 and 167 patients in STANDARD and ATRA, respectively. During consolidation therapy, 48 and 53 patients proceeded to allogeneic HCT in first CR in STANDARD and ATRA, respectively. In total, 155 and 167 patients received allogeneic HCT in first CR in STANDARD and ATRA, respectively. In addition, 149 patients received allogeneic HCT with active disease (STANDARD, <italic>n</italic>&#x02009;=&#x02009;73; ATRA, <italic>n</italic>&#x02009;=&#x02009;76) during first line therapy.</p></sec><sec id="Sec14"><title>Survival analyses</title><p>Estimated median follow-up for survival was 5.23&#x000a0;years (95&#x000a0;% CI, 5.02&#x02013;5.37) without difference according the treatment arms (<italic>p</italic>&#x02009;=&#x02009;0.69). Of the 1100 randomized patients, 808 achieved a first CR; of these, 397 relapsed, and overall, 562 died. After relapse, 88 and 90&#x000a0;% of the patients in STANDARD and ATRA were treated intensively (<italic>p</italic>&#x02009;=&#x02009;0.43). Allogeneic HCT after relapse was performed in 231 patients (ATRA, <italic>n</italic>&#x02009;=&#x02009;107; STANDARD, <italic>n</italic>&#x02009;=&#x02009;124).</p><p>Univariable survival analyses on an ITT basis revealed no significant differences for EFS (<italic>p</italic>&#x02009;=&#x02009;0.93), RFS (<italic>p</italic>&#x02009;=&#x02009;0.25) and OS (<italic>p</italic>&#x02009;=&#x02009;0.24, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>) according to the treatment arm. However, PP analyses showed a trend for superior EFS (<italic>p</italic>&#x02009;=&#x02009;0.09) and a statistically significant better OS (<italic>p</italic>&#x02009;=&#x02009;0.03, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>) for patients in ATRA compared to STANDARD, but no difference in RFS (<italic>p</italic>&#x02009;=&#x02009;0.14). In the pre-defined predictive marker study, ITT analyses (Supplementary Figure <xref rid="MOESM1" ref-type="media">1</xref>) revealed no significant impact of ATRA in the <italic>NPM1</italic>-mutated and <italic>NPM1</italic>-wildtype subgroups for EFS (<italic>p</italic>&#x02009;=&#x02009;0.17, <italic>p</italic>&#x02009;=&#x02009;0.48) for RFS (<italic>p</italic>&#x02009;=&#x02009;0.38, <italic>p</italic>&#x02009;=&#x02009;0.28) and OS (<italic>p</italic>&#x02009;=&#x02009;0.44 and <italic>p</italic>&#x02009;=&#x02009;0.70, respectively), whereas PP analyses revealed significantly improved EFS for ATRA in the <italic>NPM1</italic>-mutated subgroup (<italic>p</italic>&#x02009;=&#x02009;0.05, Supplementary Figure <xref rid="MOESM2" ref-type="media">2</xref>). Explorative analyses in molecularly defined subsets on OS revealed a significant beneficial effect on an ITT (Table <xref rid="Tab2" ref-type="table">2</xref>) and PP basis (Supplementary Figure <xref rid="MOESM3" ref-type="media">3</xref>) of ATRA in patients in the ELN favorable-risk category (<italic>p</italic>&#x02009;=&#x02009;0.05 and <italic>p</italic>&#x02009;=&#x02009;0.05, respectively), and in particular, those patients exhibiting biallelic <italic>CEBPA</italic> mutations (<italic>p</italic>&#x02009;=&#x02009;0.04 and <italic>p</italic>&#x02009;=&#x02009;0.03, respectively).<fig id="Fig2"><label>Fig. 2</label><caption><p>Survival analyses according to randomization according to intention-to-treat and per-protocol analysis</p></caption><graphic xlink:href="277_2016_2810_Fig2_HTML" id="MO2"/></fig>
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Stratified analyses of ATRA on an intention-to-treat basis by genetic risk group according to ELN recommendations and mutational status of NPM1, FLT3-ITD, DNMT3A, IDH1/2, CEBPA and RUNX1 on overall survival</p></caption><graphic xlink:href="277_2016_2810_Tab2_HTML" id="MO3"/><table-wrap-foot><p>*Log-likelihood ratio test</p></table-wrap-foot></table-wrap>
</p><p>Multivariable analyses for EFS and OS including allogeneic HCT in first CR as time-dependent variable revealed no significant impact of ATRA on an ITT basis. However, on a PP basis, ATRA was associated with a significantly (HR, 0.82; <italic>p</italic>&#x02009;=&#x02009;0.02) better OS (Tables&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>, <xref rid="Tab4" ref-type="table">4</xref>, <xref rid="Tab5" ref-type="table">5</xref>, and <xref rid="Tab6" ref-type="table">6</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Andersen-Gill regression model with the endpoint EFS analysed on an intention-to-treat basis</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>HR</th><th>95&#x000a0;% CI</th><th>
<italic>p</italic> value</th></tr></thead><tbody><tr><td colspan="4">Genetic risk according to ELN</td></tr><tr><td>&#x02003;Favorable risk&#x02019;</td><td>0.38</td><td>0.31&#x02013;0.47</td><td>&#x0003c;0.0001</td></tr><tr><td>&#x02003;Intermediate-2&#x02019;</td><td>1.05</td><td>0.86&#x02013;1.30</td><td>0.62</td></tr><tr><td>&#x02003;Adverse-risk&#x02019;</td><td>1.80</td><td>1.48&#x02013;2.18</td><td>&#x0003c;0.0001</td></tr><tr><td>s/t-AML</td><td>1.28</td><td>1.04&#x02013;1.57</td><td>0.020</td></tr><tr><td>Gender (male)</td><td>1.35</td><td>1.17&#x02013;1.56</td><td>&#x0003c;0.0001</td></tr><tr><td>WBC (Median-dichotomized)*</td><td>1.29</td><td>1.11&#x02013;1.49</td><td>0.001</td></tr><tr><td>Valproic acid</td><td>1.22</td><td>1.02&#x02013;1.47</td><td>0.032</td></tr><tr><td>Allogeneic HCT in 1<sup>st</sup> CR</td><td>0.47</td><td>0.38&#x02013;0.60</td><td>&#x0003c;0.0001</td></tr><tr><td>ATRA</td><td>0.99</td><td>0.86&#x02013;1.14</td><td>0.87</td></tr></tbody></table><table-wrap-foot><p>Variables excluded after limited backward selection in the order of their exclusion: <italic>DNMT3A</italic> mutational status (<italic>p</italic>&#x02009;=&#x02009;0.82), <italic>ASXL1</italic> mutational status (<italic>p</italic>&#x02009;=&#x02009;0.70), <italic>RUNX1</italic> mutational status (<italic>p</italic>&#x02009;=&#x02009;0.56), <italic>FLT3-TKD</italic> (<italic>p</italic>&#x02009;=&#x02009;0.48), <italic>IDH2</italic> mutational status (<italic>p</italic>&#x02009;=&#x02009;0.39), <italic>IDH1</italic> mutational status (<italic>p</italic>&#x02009;=&#x02009;0.32) and age (<italic>p</italic>&#x02009;=&#x02009;0.10)</p><p>*The median WBC of the whole cohort was 12.7 G/L</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Andersen-Gill regression model with the endpoint EFS analysed on a per-protocol basis</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>HR</th><th>95&#x000a0;% CI</th><th>
<italic>p</italic> value</th></tr></thead><tbody><tr><td colspan="4">Genetic risk according to ELN</td></tr><tr><td>&#x02003;Favorable risk</td><td>0.38</td><td>0.31&#x02013;0.47</td><td>&#x0003c;0.0001</td></tr><tr><td>&#x02003;Intermediate-2&#x02019;</td><td>1.05</td><td>0.86&#x02013;1.29</td><td>0.63</td></tr><tr><td>&#x02003;Adverse risk</td><td>1.79</td><td>1.48&#x02013;2.17</td><td>&#x0003c;0.0001</td></tr><tr><td>s/t-AML</td><td>1.28</td><td>1.04&#x02013;1.58</td><td>0.018</td></tr><tr><td>Gender (male)</td><td>1.35</td><td>1.17&#x02013;1.56</td><td>&#x0003c;0.0001</td></tr><tr><td>WBC (median-dichotomized)*</td><td>1.27</td><td>1.10&#x02013;1.47</td><td>0.001</td></tr><tr><td>Valproic acid</td><td>1.22</td><td>1.02&#x02013;1.47</td><td>0.032</td></tr><tr><td>Allogeneic HCT in 1<sup>st</sup> CR</td><td>0.47</td><td>0.37&#x02013;0.59</td><td>&#x0003c;0.0001</td></tr><tr><td>ATRA</td><td>0.88</td><td>0.76&#x02013;1.01</td><td>0.07</td></tr></tbody></table><table-wrap-foot><p>Variables excluded after limited backward selection in the order of their exclusion: <italic>DNMT3A</italic> mutational status (<italic>p</italic>=&#x02009;0.87), <italic>ASXL1</italic> mutational status (<italic>p</italic>&#x02009;=&#x02009;0.72), <italic>RUNX1</italic> mutational status (<italic>p</italic>&#x02009;=&#x02009;0.61), <italic>FLT3-TKD</italic> (<italic>p</italic>&#x02009;=&#x02009;0.53), <italic>IDH2</italic> mutational status (<italic>p</italic>&#x02009;=&#x02009;0.35), <italic>IDH1</italic> mutational status (<italic>p</italic>&#x02009;=&#x02009;0.34) and age (<italic>p</italic>&#x02009;=&#x02009;0.08)</p><p>*The median WBC of the whole cohort was 12.7 G/L</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab5"><label>Table 5</label><caption><p>Andersen-Gill regression model with the endpoint OS analysed on an intention-to-treat basis</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>HR</th><th>95&#x000a0;% CI</th><th>
<italic>p</italic> value</th></tr></thead><tbody><tr><td colspan="4">Genetic risk according to ELN</td></tr><tr><td>&#x02003;Favorable risk</td><td>0.45</td><td>0.34&#x02013;0.58</td><td align="right">&#x0003c;0.0001</td></tr><tr><td>&#x02003;Intermediate-2</td><td>1.03</td><td>0.80&#x02013;1.32</td><td align="center">0.84</td></tr><tr><td>&#x02003;Adverse risk</td><td>1.87</td><td>1.50&#x02013;2.34</td><td align="right">&#x0003c;0.0001</td></tr><tr><td>s/t-AML</td><td>1.32</td><td>1.04&#x02013;1.67</td><td align="center">0.021</td></tr><tr><td>Gender (male)</td><td>1.22</td><td>1.03&#x02013;1.44</td><td align="center">0.024</td></tr><tr><td>Age (diff. 10&#x000a0;years)</td><td>1.23</td><td>1.13&#x02013;1.34</td><td align="right">&#x0003c;0.0001</td></tr><tr><td>WBC (median-dichotomized)*</td><td>1.55</td><td>1.30&#x02013;1.85</td><td align="right">&#x0003c;0.0001</td></tr><tr><td>Valproic acid</td><td>1.36</td><td>1.10&#x02013;1.67</td><td align="center">0.004</td></tr><tr><td>Allogeneic HCT in 1<sup>st</sup> CR</td><td>0.71</td><td>0.58&#x02013;0.87</td><td align="center">0.001</td></tr><tr><td>ATRA</td><td>0.89</td><td>0.76&#x02013;1.06</td><td align="center">0.19</td></tr></tbody></table><table-wrap-foot><p>Variables excluded after limited backward selection in the order of their exclusion: <italic>DNMT3A</italic> mutational status (<italic>p</italic>&#x02009;=&#x02009;0.95), <italic>FLT3-TKD</italic> (<italic>p</italic>&#x02009;=&#x02009;0.85), <italic>ASXL1</italic> mutational status (<italic>p</italic>&#x02009;=&#x02009;0.70), <italic>RUNX1</italic> mutational status (<italic>p</italic>&#x02009;=&#x02009;0.52), <italic>IDH1</italic> mutational status (<italic>p</italic>&#x02009;=&#x02009;0.29) and <italic>IDH2</italic> mutational status (<italic>p</italic>&#x02009;=&#x02009;0.13)</p><p>*The median WBC of the whole cohort was 12.7 G/L reference group intermediate-1</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab6"><label>Table 6</label><caption><p>Andersen-Gill regression model with the endpoint OS analysed on a per-protocol basis</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>HR</th><th>95&#x000a0;% CI</th><th>
<italic>p</italic> value</th></tr></thead><tbody><tr><td colspan="4">Genetic risk according to ELN</td></tr><tr><td>&#x02003;Favorable risk</td><td>0.45</td><td>0.34&#x02013;0.58</td><td align="right">&#x0003c;0.0001</td></tr><tr><td>&#x02003;Intermediate-2</td><td>1.03</td><td>0.80&#x02013;1.33</td><td align="center">0.81</td></tr><tr><td>&#x02003;Adverse risk</td><td>1.88</td><td>1.51&#x02013;2.34</td><td align="right">&#x0003c;0.0001</td></tr><tr><td>s/t-AML</td><td>1.33</td><td>1.05&#x02013;1.68</td><td align="center">0.019</td></tr><tr><td>Gender (male)</td><td>1.22</td><td>1.03&#x02013;1.44</td><td align="center">0.019</td></tr><tr><td>Age (diff. 10&#x000a0;years)</td><td>1.24</td><td>1.14&#x02013;1.34</td><td align="right">&#x0003c;0.0001</td></tr><tr><td>WBC (median-dichotomized)*</td><td>1.51</td><td>1.26&#x02013;1.81</td><td align="right">&#x0003c;0.0001</td></tr><tr><td>Valproic acid</td><td>1.35</td><td>1.10&#x02013;1.67</td><td align="center">0.005</td></tr><tr><td>Allogeneic HCT in 1<sup>st</sup> CR</td><td>0.71</td><td>0.58&#x02013;0.88</td><td align="center">0.001</td></tr><tr><td>ATRA</td><td>0.81</td><td>0.69&#x02013;0.96</td><td align="center">0.017</td></tr></tbody></table><table-wrap-foot><p>Variables excluded after limited backward selection in the order of their exclusion: <italic>DNMT3A</italic> mutational status (<italic>p</italic>&#x02009;=&#x02009;0.87), <italic>ASXL1</italic> mutational status (<italic>p</italic>&#x02009;=&#x02009;0.70), <italic>RUNX1</italic> mutational status (<italic>p</italic>&#x02009;=&#x02009;0.61), FlT3-tKd (<italic>p</italic>&#x02009;=&#x02009;0.53), <italic>IDH2</italic> mutational status (<italic>p</italic>&#x02009;=&#x02009;0.35), <italic>IDH1</italic> mutational status (<italic>p</italic>&#x02009;=&#x02009;0.34) and age (<italic>p</italic>&#x02009;=&#x02009;0.08)</p><p>*The median WBC of the whole cohort was 12.7 G/L reference group intermediate-1</p></table-wrap-foot></table-wrap>
</p><p>Overall, 473 patients relapsed after achieving a first remission either on the protocol (<italic>n</italic>&#x02009;=&#x02009;397) or after salvage therapy (<italic>n</italic>&#x02009;=&#x02009;76). According to ELN-risk groups, 130 patients had a favorable risk (CBF-AML, biallelic mutated <italic>CEBPA</italic>, mutant <italic>NPM1</italic>/<italic>FLT3</italic>-ITDneg) and 263 patients had no favorable risk. Of the relapsed patients with favorable risk, 95 patients received allogeneic HCT after relapse; of the 6 patients who had been transplanted in the first CR, 4 patients received a second allogeneic HCT and 2 patients received autologous HCT; and 27 patients were treated with chemotherapy only. Relapsed patients within all other ELN risk groups were treated after relapse with allogeneic HCT (<italic>n</italic>&#x02009;=&#x02009;116) or chemotherapy (<italic>n</italic>&#x02009;=&#x02009;78); of 78 patients who had been transplanted in first CR, 24 patients received second allogeneic HCT and 54 patients chemotherapy only. The second CR rates, also including CRs achieved after allogeneic HCT, were not significantly different in STANDARD and ATRA with 65 % (45/69) and 73&#x000a0;% (45/61) in the favorable-risk group, and 48 % (67/141) and 54&#x000a0;% (66/122) in other ELN-risk groups, respectively. In contrast, treatment with ATRA during first-line therapy had a major impact on OS after relapse. Patients in the favorable-risk group had a significantly superior OS after relapse if they had received ATRA (ITT, <italic>p</italic>&#x02009;=&#x02009;0.006; PP, <italic>p</italic>&#x02009;=&#x02009;0.02; Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>) during the first-line therapy, whereas this was not the case in the other ELN-risk groups (ITT, <italic>p</italic>&#x02009;=&#x02009;0.98; PP, <italic>p</italic>&#x02009;=&#x02009;0.71; Fig. <xref rid="Fig3" ref-type="fig">3b</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>Survival after relapse according to European LeukemiaNet (ELN) classification analyzed on an intention-to-treat basis. <bold>a</bold> ELN favorable-risk group; <bold>b</bold> all other ELN risk groups</p></caption><graphic xlink:href="277_2016_2810_Fig3_HTML" id="MO4"/></fig>
</p></sec></sec><sec id="Sec15" sec-type="discussion"><title>Discussion</title><p>We previously reported that ATRA given in combination with intensive chemotherapy improves survival in older patients with AML [<xref ref-type="bibr" rid="CR19">19</xref>]. The objectives of this trial were to perform a confirmatory study in a younger patient population and to endorse mutant <italic>NPM1</italic> as a predictive factor for response to ATRA [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p>Induction therapy consisted of idarubicin, etoposide and cytarabine (ICE) with or without ATRA. Based on the early preclinical data, we decided to start ATRA at day 6, that is, after most of the cytotoxic drugs were administered; furthermore, we reduced the daily dose to 15&#x000a0;mg/m<sup>2</sup> at day 9 to avoid undue toxicity. Due to the open-label character of the study, we implemented in the protocol predefined ITT as well as PP analyses. Our results show that the addition of ATRA to intensive induction therapy is feasible with three days of 45&#x000a0;mg/m<sup>2</sup> followed by a dose reduction to 15&#x000a0;mg/m<sup>2</sup> and not associated with relevant additional toxicity. This is in contrast to the results reported in the NCRI AML16 trial, in which continuous high doses of ATRA (45&#x000a0;mg/m<sup>2</sup>) have led to excessive toxicity in 616 randomized patients with a significant increase in the 30-day mortality rate of 20&#x000a0;% in the ATRA arm as compared to 12&#x000a0;% in the standard arm (<italic>p</italic>&#x02009;=&#x02009;0.005) [<xref ref-type="bibr" rid="CR38">38</xref>].</p><p>Overall, we were not able to show a significant beneficial effect of ATRA on an IIT basis on the primary endpoint EFS and the secondary endpoints CR rate, RFS and OS. In addition, we were also not able to confirm, on an ITT basis, the predictive value of NPM1 mutational status on the beneficial effect of ATRA on clinical endpoints. Thus, our data confirm the results from MRC showing no impact of ATRA on clinical endpoints and in distinct molecular subgroups including mutated <italic>NPM1</italic> with or without <italic>FLT3</italic>-ITD [<xref ref-type="bibr" rid="CR21">21</xref>]. However, PP analyses revealed some efficacy of ATRA in the total cohort for OS (<italic>p</italic>&#x02009;=&#x02009;0.03) and for EFS in <italic>NPM1-</italic>mutated AML (<italic>p</italic>&#x02009;=&#x02009;0.05). Although PP analyses may be biased, these results are supported by multivariable models accounting for important base-line variables and allogeneic HCT which was included as a time-dependent covariable. Thus, to some extent, our previous data on the beneficial clinical effect of ATRA overall [<xref ref-type="bibr" rid="CR19">19</xref>] as well as in a genetically defined subgroup [<xref ref-type="bibr" rid="CR20">20</xref>] were supported by the results of the current study.</p><p>Our clinical results are supported by recent <italic>in vitro</italic> data in cell lines and primary AML blasts showing the ability of ATRA to induce a significant amount of apoptosis in some (3 out of 11) primary leukemia samples from patients with <italic>NPM1</italic> mutation which was potentiated by combination with ATO [<xref ref-type="bibr" rid="CR13">13</xref>]. In addition, ATRA alone was also able to induce a marked selective downregulation of NPM1 mutant oncoprotein indicated by the appearance of active caspase-8 fragment and cleaved poly(ADP-ribose)polymerase (PARP). Again, the combination of ATRA with ATO was even more effective [<xref ref-type="bibr" rid="CR13">13</xref>]. These findings were similarly reported by others showing that ATRA and/or ATO were able to induce proteasomal degradation of mutant NPM1 in AML cell lines or primary samples leading to differentiation and apoptosis [<xref ref-type="bibr" rid="CR12">12</xref>]. Based on the <italic>in vitro</italic> data, 5 patients with <italic>NPM1</italic>-mutated AML were treated with ATRA/ATO resulting in a transient antileukemic effect [<xref ref-type="bibr" rid="CR12">12</xref>]. Of note, in contrast to previous <italic>in vitro</italic> data, Martelli et al. showed an increased sensitivity upon treatment with ATRA/ATO 24 to 48&#x000a0;h before treatment with daunorubicin [<xref ref-type="bibr" rid="CR13">13</xref>]. These data support further exploration of ATRA in combination with ATO and an anthracycline in AML with mutated <italic>NPM1</italic>.</p><p>Somewhat surprisingly, the beneficial effect of ATRA in AML with mutated <italic>NPM1</italic> on EFS based on PP analysis did not translate into a beneficial effect on OS. Rather both subpopulations, <italic>NPM1</italic>-wildtype and <italic>NPM1</italic>-mutated AML, contributed to the significantly improved OS (<italic>p</italic>&#x02009;=&#x02009;0.03) in PP analyses (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). As there was no significant impact of ATRA on EFS and RFS, this observation prompted us to analyze outcome after relapse. Most patients received allogeneic HCT after relapse, 76&#x000a0;% in the ELN favorable-risk group and 53&#x000a0;% in the other ELN risk groups. There was a major beneficial effect of ATRA analyzed on an ITT and a PP basis in the ELN favorable-risk group with a significantly better OS after relapse in those patients randomized to and treated with ATRA, whereas no effect was seen in the other ELN risk groups (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, Fig. 4). As no significant difference in the second CR rates were evident and most patients received an allogeneic HCT after relapse, the effect of ATRA on outcome after relapse may be explained by preventing further relapses. One hypothesis could be that ATRA modulates antigen presentation in the context of mucosal immunity [<xref ref-type="bibr" rid="CR39">39</xref>] in patients undergoing allogeneic HCT.</p><p>In conclusion, ATRA in combination with intensive induction and consolidation therapy as used in our study can be safely administered. In ITT analysis, no impact on outcome was demonstrated except for a beneficial effect of ATRA in ELN favorable-risk patients. In contrast, in PP analysis, ATRA was associated with an improved EFS in <italic>NPM1</italic>-mutated AML as well as OS in all patients. In addition, ATRA given during first CR impacted on survival in patients with ELN favorable-risk receiving allogeneic HCT after relapse.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec16"><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="277_2016_2810_MOESM1_ESM.pdf"><label>ESM 1</label><caption><p>Supplementary Figure 1. Stratified analyses of ATRA on an intention-to-treat basis by genetic risk group according to ELN recommendations and mutational status of <italic>NPM1</italic>, <italic>FLT3</italic>-ITD, <italic>DNMT3A</italic>, <italic>IDH1/2</italic>, <italic>CEBPA</italic>, <italic>RUNX1</italic> on event free survival. *log-likelihood ratio test (PDF 1312&#x000a0;kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="277_2016_2810_MOESM2_ESM.pdf"><label>ESM 2</label><caption><p>Supplementary Figure 2. Stratified analyses of ATRA on a per-protocol basis by genetic risk group according to ELN recommendations and mutational status of <italic>NPM1</italic>, <italic>FLT3</italic>-ITD, <italic>DNMT3A</italic>, <italic>IDH1/2</italic>, <italic>CEBPA</italic>, <italic>RUNX1</italic> on event free survival. *log-likelihood ratio test (PDF 1316&#x000a0;kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="277_2016_2810_MOESM3_ESM.pdf"><label>ESM 3</label><caption><p>Supplementary Figure 3: Stratified analyses of ATRA on an per-protocol basis by genetic risk group according to ELN recommendations and mutational status of <italic>NPM1</italic>, <italic>FLT3</italic>-ITD, <italic>DNMT3A</italic>, <italic>IDH1/2</italic>, <italic>CEBPA</italic>, <italic>RUNX1</italic> on overall survival. *log-likelihood ratio test (PDF 1316&#x000a0;kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="277_2016_2810_MOESM4_ESM.pdf"><label>ESM 4</label><caption><p>(PDF 70&#x000a0;kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="277_2016_2810_MOESM5_ESM.pdf"><label>ESM 5</label><caption><p>(PDF 8&#x000a0;kb)</p></caption></media></supplementary-material>
</p></sec></sec></body><back><fn-group><fn><p>Presented in part at the 53rd Annual Meeting of the American Society of Hematology, 2011 and the 19th Congress of the European Hematology Association, 2014.</p></fn></fn-group><ack><title>Acknowledgment</title><p>This work was supported by grants 01GI9981 [Network of Competence Acute and Chronic Leukemias], and 01KG0605 [IPD-Meta-Analysis: A model-based hierarchical prognostic system for adult patients with acute myeloid leukemia (AML)] from the German Bundesministerium f&#x000fc;r Bildung und Forschung (BMBF), the German Research Foundation (DFG FI405/5-1, BU 1339/3-1 and BU 1339/5-1, SFB 1074 B3), the Deutsche Jos&#x000e9; Carreras Leuk&#x000e4;mie-Stiftung (DJCLS H 05/02), and an unrestricted grant from Pfizer. We are also grateful to all members of the German-Austrian AML Study Group (AMLSG) for providing leukemia specimens and clinical data; a list of AMLSG institutions and investigators participating in this study appears in the supplemental Appendix.</p></ack><notes notes-type="COI-statement"><title>Compliance with ethical standards</title><sec id="FPar1"><title>Conflicts of interest</title><p>Authors indicated no potential conflict of interest.</p></sec><sec id="FPar2"><title>Authors&#x02019; contribution</title><p>Conception and Design: Richard F. Schlenk, Michael L&#x000fc;bbert, Hartmut D&#x000f6;hner</p><p>Provision of study materials or patients: Richard F. Schlenk, Michael L&#x000fc;bbert, J&#x000fc;rgen Krauter, Thomas Kindler, Hans Martin, Helmut R. Salih, Andrea K&#x000fc;ndgen, Heinz-A. Horst, Peter Brossart, Katharina G&#x000f6;tze, David Nachbaur, Mohammed Wattad, Claus-Henning K&#x000f6;hne, Walter Fiedler, Martin Bentz, Gerald Wulf, Gerhard Held, Bernd Hertenstein, Hans Salwender, Verena I Gaidzik, Brigitte Schlegelberger, Konstanze D&#x000f6;hner, Arnold Ganser, Hartmut D&#x000f6;hner.</p><p>Collection and assembly of data: Richard F. Schlenk, Alexander Lamparter, Daniela Weber.</p><p>Data analysis and interpretation: Richard F. Schlenk, Alexander Lamparter, Axel Benner, Hartmut D&#x000f6;hner.</p><p>Manuscript writing: Richard F. Schlenk, Hartmut D&#x000f6;hner.</p><p>Final approval of manuscript: Richard F. Schlenk, Michael L&#x000fc;bbert, Axel Benner, Alexander Lamparter, J&#x000fc;rgen Krauter, Thomas Kindler, Hans Martin, Helmut R. Salih, Andrea K&#x000fc;ndgen, Heinz-A. Horst, Peter Brossart, Katharina G&#x000f6;tze, David Nachbaur, Mohammed Wattad, Claus-Henning K&#x000f6;hne, Walter Fiedler, Martin Bentz, Gerald Wulf, Gerhard Held, Bernd Hertenstein, Hans Salwender, Verena I Gaidzik, Brigitte Schlegelberger, Daniela Weber, Konstanze D&#x000f6;hner, Arnold Ganser, Hartmut D&#x000f6;hner.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lo-Coco</surname><given-names>F</given-names></name><name><surname>Avvisati</surname><given-names>G</given-names></name><name><surname>Vignetti</surname><given-names>M</given-names></name><name><surname>Thiede</surname><given-names>C</given-names></name><name><surname>Orlando</surname><given-names>SM</given-names></name><name><surname>Iacobelli</surname><given-names>S</given-names></name><etal/></person-group><article-title>Retinoic acid and arsenic trioxide for acute promyelocytic leukemia</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><issue>2</issue><fpage>111</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1300874</pub-id><pub-id pub-id-type="pmid">23841729</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lo-Coco</surname><given-names>F</given-names></name><name><surname>Di Donato</surname><given-names>L</given-names></name><collab>GIMEMA</collab><name><surname>Schlenk</surname><given-names>RF</given-names></name><collab>German&#x02013;Austrian Acute Myeloid Leukemia Study Group and Study Alliance Leukemia</collab></person-group><article-title>Targeted therapy alone for acute promyelocytic leukemia</article-title><source>N Engl J Med</source><year>2016</year><volume>374</volume><issue>12</issue><fpage>1197</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1056/NEJMc1513710</pub-id><pub-id pub-id-type="pmid">27007970</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>ZB</given-names></name><name><surname>Minden</surname><given-names>MD</given-names></name><name><surname>McCulloch</surname><given-names>EA</given-names></name></person-group><article-title>Direct evidence for the participation of bcl-2 in the regulation by retinoic acid of the Ara-C sensitivity of leukemic stem cells</article-title><source>Leukemia</source><year>1995</year><volume>9</volume><fpage>1667</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">7564507</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>GS</given-names></name><name><surname>Minden</surname><given-names>MD</given-names></name><name><surname>McCulloch</surname><given-names>EA</given-names></name></person-group><article-title>Influence of schedule on regulated sensitivity of AML blasts to cytosine arabinoside</article-title><source>Leukemia</source><year>1993</year><volume>7</volume><fpage>1012</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">7686602</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreeff</surname><given-names>M</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Konopleva</surname><given-names>M</given-names></name><name><surname>Estrov</surname><given-names>Z</given-names></name><name><surname>Snell</surname><given-names>VE</given-names></name><etal/></person-group><article-title>Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid</article-title><source>Leukemia</source><year>1999</year><volume>13</volume><fpage>1881</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2401573</pub-id><pub-id pub-id-type="pmid">10557066</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ketley</surname><given-names>NJ</given-names></name><name><surname>Allen</surname><given-names>PD</given-names></name><name><surname>Kelsey</surname><given-names>SM</given-names></name><name><surname>Newland</surname><given-names>AC</given-names></name></person-group><article-title>Modulation of idarubicin-induced apoptosis in human acute myeloid leukemia blasts by all-trans retinoic acid, 1,25(OH)2 vitamin D3, and granulocyte&#x02013;macrophage colony-stimulating factor</article-title><source>Blood</source><year>1997</year><volume>90</volume><fpage>4578</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">9373269</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>ZB</given-names></name><name><surname>Minden</surname><given-names>MD</given-names></name><name><surname>McCulloch</surname><given-names>EA</given-names></name></person-group><article-title>Phosphorylation of BCL-2 after exposure of human leukemic cells to retinoic acid</article-title><source>Blood</source><year>1998</year><volume>92</volume><fpage>1768</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">9716607</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>BZ</given-names></name><name><surname>Milella</surname><given-names>M</given-names></name><name><surname>Altieri</surname><given-names>DC</given-names></name><name><surname>Andreeff</surname></name></person-group><article-title>Cytokine-regulated expression of survivin in myeloid leukemia</article-title><source>Blood</source><year>2001</year><volume>97</volume><fpage>2784</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1182/blood.V97.9.2784</pub-id><pub-id pub-id-type="pmid">11313272</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boutzen</surname><given-names>H</given-names></name><name><surname>Saland</surname><given-names>E</given-names></name><name><surname>Larrue</surname><given-names>C</given-names></name><name><surname>de Toni</surname><given-names>F</given-names></name><name><surname>Gales</surname><given-names>L</given-names></name><name><surname>Castelli</surname><given-names>FA</given-names></name><etal/></person-group><article-title>Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia</article-title><source>J Exp Med</source><year>2016</year><volume>213</volume><issue>4</issue><fpage>483</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1084/jem.20150736</pub-id><pub-id pub-id-type="pmid">26951332</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradbury</surname><given-names>DA</given-names></name><name><surname>Aldington</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>YM</given-names></name><name><surname>Russell</surname><given-names>NH</given-names></name></person-group><article-title>Down-regulation of bcl-2 in AML blasts by alltrans retinoic acid and its relationship to CD34 antigen expression</article-title><source>Br J Haematol.</source><year>1996</year><volume>94</volume><fpage>671</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2141.1996.d01-1838.x</pub-id><pub-id pub-id-type="pmid">8826891</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balusu</surname><given-names>R</given-names></name><name><surname>Fiskus</surname><given-names>W</given-names></name><name><surname>Rao</surname><given-names>R</given-names></name><name><surname>Chong</surname><given-names>DG</given-names></name><name><surname>Nalluri</surname><given-names>S</given-names></name><name><surname>Mudunuru</surname><given-names>U</given-names></name><etal/></person-group><article-title>Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1</article-title><source>Blood</source><year>2011</year><volume>118</volume><issue>11</issue><fpage>3096</fpage><lpage>3106</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-09-309674</pub-id><pub-id pub-id-type="pmid">21719597</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hajj</surname><given-names>HE</given-names></name><name><surname>Dassouki</surname><given-names>Z</given-names></name><name><surname>Berthier</surname><given-names>C</given-names></name><name><surname>Raffoux</surname><given-names>E</given-names></name><name><surname>Ades</surname><given-names>L</given-names></name><name><surname>Legrand</surname><given-names>O</given-names></name><etal/></person-group><article-title>Retinoic acid and arsenic trioxide trigger degradation of mutated NPM-1 resulting in apoptosis of AML cells</article-title><source>Blood</source><year>2015</year><volume>125</volume><issue>22</issue><fpage>3447</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-11-612416</pub-id><pub-id pub-id-type="pmid">25800051</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martelli</surname><given-names>MP</given-names></name><name><surname>Gionfriddo</surname><given-names>I</given-names></name><name><surname>Mezzasoma</surname><given-names>F</given-names></name><name><surname>Milano</surname><given-names>F</given-names></name><name><surname>Pierangeli</surname><given-names>S</given-names></name><name><surname>Mulas</surname><given-names>F</given-names></name><etal/></person-group><article-title>Arsenic trioxide and all-trans-retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells</article-title><source>Blood</source><year>2015</year><volume>125</volume><issue>22</issue><fpage>3455</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-11-611459</pub-id><pub-id pub-id-type="pmid">25795919</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venditti</surname><given-names>A</given-names></name><name><surname>Stasi</surname><given-names>R</given-names></name><name><surname>Del Poeta</surname><given-names>G</given-names></name><name><surname>Buccisano</surname><given-names>F</given-names></name><name><surname>Aronica</surname><given-names>G</given-names></name><name><surname>Bruno</surname><given-names>A</given-names></name><etal/></person-group><article-title>All-trans retinoic acid and low-dose cytosine arabinoside for the treatment of poor prognosis acute myeloid leukemia</article-title><source>Leukemia</source><year>1995</year><volume>9</volume><fpage>1121</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">7630182</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Estey</surname><given-names>EH</given-names></name><name><surname>Thall</surname><given-names>PF</given-names></name><name><surname>Pierce</surname><given-names>S</given-names></name><name><surname>Cortes</surname><given-names>J</given-names></name><name><surname>Beran</surname><given-names>M</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name><etal/></person-group><article-title>Randomized phase II study of fludarabine&#x02009;+&#x02009;cytosine arabinoside&#x02009;+&#x02009;idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome</article-title><source>Blood</source><year>1999</year><volume>93</volume><fpage>2478</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">10194425</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnett</surname><given-names>AK</given-names></name><name><surname>Milligan</surname><given-names>D</given-names></name><name><surname>Hills</surname><given-names>RK</given-names></name><name><surname>Goldstone</surname><given-names>AH</given-names></name><name><surname>Prentice</surname><given-names>AG</given-names></name><name><surname>Wheatley</surname><given-names>K</given-names></name><etal/></person-group><article-title>Does all-trans retinoic acid (ATRA) have a role in non-APL acute myeloid leukaemia? Results from 1666 patients in three MRC trials</article-title><source>Blood</source><year>2004</year><volume>104</volume><fpage>1794</fpage></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnett</surname><given-names>AK</given-names></name><name><surname>Milligan</surname><given-names>D</given-names></name><name><surname>Prentice</surname><given-names>AG</given-names></name><name><surname>Goldstone</surname><given-names>AH</given-names></name><name><surname>McMullin</surname><given-names>MF</given-names></name><name><surname>Hills</surname><given-names>RK</given-names></name><etal/></person-group><article-title>A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and highrisk myelodysplastic syndrome in patients not considered fit for intensive treatment</article-title><source>Cancer</source><year>2007</year><volume>109</volume><fpage>1114</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1002/cncr.22496</pub-id><pub-id pub-id-type="pmid">17315155</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milligan</surname><given-names>DW</given-names></name><name><surname>Wheatley</surname><given-names>K</given-names></name><name><surname>Littlewood</surname><given-names>T</given-names></name><name><surname>Craig</surname><given-names>JI</given-names></name><name><surname>Burnett</surname><given-names>AK</given-names></name><collab>NCRI Haematological Oncology Clinical Studies Group</collab></person-group><article-title>Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AMLHR randomized trial</article-title><source>Blood</source><year>2006</year><volume>107</volume><fpage>4614</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1182/blood-2005-10-4202</pub-id><pub-id pub-id-type="pmid">16484584</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlenk</surname><given-names>RF</given-names></name><name><surname>Fr&#x000f6;hling</surname><given-names>S</given-names></name><name><surname>Hartmann</surname><given-names>F</given-names></name><name><surname>Glasmacher</surname><given-names>A</given-names></name><name><surname>Fischer</surname><given-names>JT</given-names></name><name><surname>del Valle y Fuentes</surname><given-names>F</given-names></name><etal/></person-group><article-title>Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia</article-title><source>Leukemia</source><year>2004</year><volume>18</volume><fpage>1798</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2403528</pub-id><pub-id pub-id-type="pmid">15385923</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlenk</surname><given-names>RF</given-names></name><name><surname>D&#x000f6;hner</surname><given-names>K</given-names></name><name><surname>Kneba</surname><given-names>M</given-names></name><name><surname>G&#x000f6;tze</surname><given-names>K</given-names></name><name><surname>Hartmann</surname><given-names>F</given-names></name><name><surname>Del Valle</surname><given-names>F</given-names></name><etal/></person-group><article-title>Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia &#x02013; results from AMLSG Trial AML HD98B</article-title><source>Haematologica.</source><year>2009</year><volume>94</volume><fpage>54</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.3324/haematol.13378</pub-id><pub-id pub-id-type="pmid">19059939</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnett</surname><given-names>AK</given-names></name><name><surname>Hills</surname><given-names>RK</given-names></name><name><surname>Green</surname><given-names>C</given-names></name><name><surname>Jenkinson</surname><given-names>S</given-names></name><name><surname>Koo</surname><given-names>K</given-names></name><name><surname>Patel</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA</article-title><source>Blood.</source><year>2010</year><volume>115</volume><fpage>948</fpage><lpage>956</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-08-236588</pub-id><pub-id pub-id-type="pmid">19965647</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tassara</surname><given-names>M</given-names></name><name><surname>D&#x000f6;hner</surname><given-names>K</given-names></name><name><surname>Brossart</surname><given-names>P</given-names></name><name><surname>Held</surname><given-names>G</given-names></name><name><surname>G&#x000f6;tze</surname><given-names>K</given-names></name><name><surname>Horst</surname><given-names>HA</given-names></name><etal/></person-group><article-title>Valproic acid in combination with all-trans retinoic acid and intensive induction therapy for acute myeloid leukemia in older patients</article-title><source>Blood</source><year>2014</year><volume>123</volume><issue>26</issue><fpage>4027</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1182/blood-2013-12-546283</pub-id><pub-id pub-id-type="pmid">24797300</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jaffe</surname><given-names>ES</given-names></name><name><surname>Harris</surname><given-names>NL</given-names></name><name><surname>Stein</surname><given-names>H</given-names></name><name><surname>Vardiman</surname><given-names>JW</given-names></name></person-group><source>Pathology and genetics of tumours of haematopoietic and lymphoid tissues</source><year>2001</year><edition>3</edition><publisher-loc>Lyon</publisher-loc><publisher-name>IARC Press</publisher-name></element-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Mitelman F (ed): ISCN (1995): An international system for human cytogenetic nomenclature. Basel, Switzerland, Karger, 1995</mixed-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlenk</surname><given-names>RF</given-names></name><name><surname>D&#x000f6;hner</surname><given-names>K</given-names></name><name><surname>Krauter</surname><given-names>J</given-names></name><name><surname>Fr&#x000f6;hling</surname><given-names>S</given-names></name><name><surname>Corbacioglu</surname><given-names>A</given-names></name><name><surname>Bullinger</surname><given-names>L</given-names></name><etal/></person-group><article-title>Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><issue>18</issue><fpage>1909</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa074306</pub-id><pub-id pub-id-type="pmid">18450602</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlenk</surname><given-names>RF</given-names></name><name><surname>Dohner</surname><given-names>K</given-names></name><name><surname>Mack</surname><given-names>S</given-names></name><name><surname>Stoppel</surname><given-names>M</given-names></name><name><surname>Kir&#x000e1;ly</surname><given-names>F</given-names></name><name><surname>G&#x000f6;tze</surname><given-names>K</given-names></name><etal/></person-group><article-title>Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><issue>30</issue><fpage>4642</fpage><lpage>4648</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.28.6856</pub-id><pub-id pub-id-type="pmid">20805454</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheson</surname><given-names>BD</given-names></name><name><surname>Bennett</surname><given-names>JM</given-names></name><name><surname>Kopecky</surname><given-names>KJ</given-names></name><name><surname>B&#x000fc;chner</surname><given-names>T</given-names></name><name><surname>Willman</surname><given-names>CL</given-names></name><name><surname>Estey</surname><given-names>EH</given-names></name><etal/></person-group><article-title>Revised recommendations of the International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia</article-title><source>J Clin Oncol</source><year>2003</year><volume>21</volume><issue>24</issue><fpage>4642</fpage><lpage>4649</lpage><pub-id pub-id-type="doi">10.1200/JCO.2003.04.036</pub-id><pub-id pub-id-type="pmid">14673054</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schemper</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>TL</given-names></name></person-group><article-title>A note on quantifying follow-up in studies of failure time</article-title><source>Control Clin Trials</source><year>1996</year><volume>17</volume><issue>4</issue><fpage>343</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1016/0197-2456(96)00075-X</pub-id><pub-id pub-id-type="pmid">8889347</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>P</given-names></name><name><surname>Gill</surname><given-names>RD</given-names></name></person-group><article-title>Cox&#x02019;s regression model for counting processes: a large sample study</article-title><source>Ann Stat</source><year>1982</year><volume>10</volume><fpage>1100</fpage><lpage>1120</lpage><pub-id pub-id-type="doi">10.1214/aos/1176345976</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x000f6;hner</surname><given-names>H</given-names></name><name><surname>Estey</surname><given-names>EH</given-names></name><name><surname>Amadori</surname><given-names>S</given-names></name><name><surname>Appelbaum</surname><given-names>FR</given-names></name><name><surname>B&#x000fc;chner</surname><given-names>T</given-names></name><name><surname>Burnett</surname><given-names>AK</given-names></name><etal/></person-group><article-title>European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet</article-title><source>Blood</source><year>2010</year><volume>115</volume><issue>3</issue><fpage>453</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-07-235358</pub-id><pub-id pub-id-type="pmid">19880497</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Harrell</surname><given-names>FE</given-names></name></person-group><source>Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis</source><year>2001</year><publisher-loc>New York</publisher-loc><publisher-name>Springer</publisher-name></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>R Development Core Team</collab></person-group><source>R: A language and environment for statistical computing</source><year>2009</year><publisher-loc>Vienna</publisher-loc><publisher-name>R Foundation for Statistical Computing</publisher-name></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000fc;chner</surname><given-names>T</given-names></name><name><surname>Schlenk</surname><given-names>RF</given-names></name><name><surname>Schaich</surname><given-names>M</given-names></name><name><surname>D&#x000f6;hner</surname><given-names>K</given-names></name><name><surname>Krahl</surname><given-names>R</given-names></name><name><surname>Krauter</surname><given-names>J</given-names></name><etal/></person-group><article-title>Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><issue>29</issue><fpage>3604</fpage><lpage>3610</lpage><pub-id pub-id-type="doi">10.1200/JCO.2012.42.2907</pub-id><pub-id pub-id-type="pmid">22965967</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnett</surname><given-names>AK</given-names></name><name><surname>Hills</surname><given-names>RK</given-names></name><name><surname>Friis</surname><given-names>LS</given-names></name><name><surname>Kjeldsen</surname><given-names>L</given-names></name><name><surname>Milligan</surname><given-names>D</given-names></name><name><surname>Hunter</surname><given-names>AE</given-names></name><etal/></person-group><article-title>The ATRA question in AML: lack of benefit overall or in any molecular subgroup in the NCRI AML16 trial</article-title><source>Blood</source><year>2013</year><volume>122</volume><issue>21</issue><fpage>493</fpage></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lencer</surname><given-names>WI</given-names></name><name><surname>von Andrian</surname><given-names>UH</given-names></name></person-group><article-title>Eliciting mucosal immunity</article-title><source>N Engl J Med</source><year>2011</year><volume>365</volume><issue>12</issue><fpage>1151</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1056/NEJMcibr1107816</pub-id><pub-id pub-id-type="pmid">21992128</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaidzik</surname><given-names>VI</given-names></name><name><surname>Schlenk</surname><given-names>RF</given-names></name><name><surname>Paschka</surname><given-names>P</given-names></name><name><surname>St&#x000f6;lzle</surname><given-names>A</given-names></name><name><surname>Sp&#x000e4;th</surname><given-names>D</given-names></name><name><surname>Kuendgen</surname><given-names>A</given-names></name><etal/></person-group><article-title>Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG)</article-title><source>Blood</source><year>2013</year><volume>121</volume><issue>23</issue><fpage>4769</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-10-461624</pub-id><pub-id pub-id-type="pmid">23632886</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaidzik</surname><given-names>VI</given-names></name><name><surname>Teleanu</surname><given-names>V</given-names></name><name><surname>Papaemmanuil</surname><given-names>E</given-names></name><name><surname>Weber</surname><given-names>D</given-names></name><name><surname>Paschka</surname><given-names>P</given-names></name><name><surname>Hahn</surname><given-names>J</given-names></name><etal/></person-group><article-title>RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features</article-title><source>Leukemia</source><year>2016</year></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paschka</surname><given-names>P</given-names></name><name><surname>Schlenk</surname><given-names>RF</given-names></name><name><surname>Gaidzik</surname><given-names>VI</given-names></name><name><surname>Habdank</surname><given-names>M</given-names></name><name><surname>Kr&#x000f6;nke</surname><given-names>J</given-names></name><name><surname>Bullinger</surname><given-names>L</given-names></name><etal/></person-group><article-title>IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><issue>22</issue><fpage>3636</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.28.3762</pub-id><pub-id pub-id-type="pmid">20567020</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paschka</surname><given-names>P</given-names></name><name><surname>Schlenk</surname><given-names>RF</given-names></name><name><surname>Gaidzik</surname><given-names>VI</given-names></name><name><surname>Herzig</surname><given-names>JK</given-names></name><name><surname>Aulitzky</surname><given-names>T</given-names></name><name><surname>Bullinger</surname><given-names>L</given-names></name><etal/></person-group><article-title>ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group</article-title><source>Haematologica</source><year>2015</year><volume>100</volume><issue>3</issue><fpage>324</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.3324/haematol.2014.114157</pub-id><pub-id pub-id-type="pmid">25596267</pub-id></element-citation></ref></ref-list></back></article>